Core Viewpoint - Wall Street anticipates flat earnings for Chewy (CHWY) in the upcoming quarter, with revenues expected to increase slightly, making the comparison between actual results and estimates crucial for stock price movement [1][2]. Earnings Expectations - Chewy is projected to report earnings of $0.28 per share, unchanged from the same quarter last year, with revenues estimated at $3.26 billion, reflecting a 0.3% increase year-over-year [3]. - The consensus EPS estimate has remained stable over the past 30 days, indicating no significant changes in analysts' outlooks [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that Chewy has a positive Earnings ESP of +0.36%, suggesting analysts have recently become more optimistic about the company's earnings [12]. - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3, which enhances predictive power [10]. Historical Performance - Chewy has exceeded consensus EPS estimates in three out of the last four quarters, with a notable surprise of +6.67% in the last reported quarter [13][14]. Conclusion - Chewy is viewed as a strong candidate for an earnings beat, but investors should consider additional factors that may influence stock performance beyond earnings results [15][17].

Core Viewpoint - TopBuild is well-positioned to continue its earnings-beat streak in the upcoming report, having surpassed earnings estimates consistently in recent quarters [1]. Earnings Performance - In the last reported quarter, TopBuild achieved earnings of $5.36 per share, exceeding the Zacks Consensus Estimate of $5.22 per share by 2.68% [2]. - In the previous quarter, the company reported earnings of $5.31 per share against an expected $5.07 per share, resulting in a surprise of 4.73% [2]. Earnings Estimates and Predictions - Estimates for TopBuild have been trending higher, influenced by its history of earnings surprises, and it currently has a positive Zacks Earnings ESP of +0.19%, indicating bullish sentiment among analysts [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) suggests a strong likelihood of another earnings beat in the upcoming report scheduled for February 26, 2026 [8]. Earnings ESP Insights - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate [7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced positive surprises nearly 70% of the time, indicating a high probability of beating consensus estimates [6].

Company Overview - TG Therapeutics (TGTX) is expected to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings projected at $0.35 per share, reflecting a +133.3% change, and revenues expected to be $189.4 million, up 75.1% from the previous year [3]. Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 12.93% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][12]. - The Most Accurate Estimate for TG Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.43%, which complicates the prediction of an earnings beat [12]. Earnings Surprise History - In the last reported quarter, TG Therapeutics had a significant earnings surprise, posting earnings of $2.43 per share against an expected $0.24, resulting in a surprise of +912.50% [13]. - Over the last four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Context - In comparison, Mirum Pharmaceuticals, Inc. (MIRM) is expected to post earnings of $0.02 per share for the same quarter, indicating a year-over-year change of +104.1%, with revenues projected at $141.27 million, up 42.1% [18]. - Mirum Pharmaceuticals has seen a significant upward revision of its EPS estimate by 50.9% over the last 30 days, resulting in an Earnings ESP of +675.00%, suggesting a strong likelihood of beating the consensus EPS estimate [19][20].

Core Viewpoint - Life360 (LIF) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the consensus outlook indicating a significant potential impact on its stock price based on actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.33 per share, reflecting a year-over-year increase of +230% [3]. - Revenues are projected to reach $144 million, which is a 24.6% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 40% over the last 30 days, indicating a reassessment by analysts of their initial estimates [4]. - The Most Accurate Estimate for Life360 aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Life360 currently holds a Zacks Rank of 4 (Sell), complicating the prediction of an earnings beat [12]. Historical Performance - Life360 has successfully beaten consensus EPS estimates in the last four quarters, with a notable surprise of +266.67% in the most recent quarter [13][14]. Conclusion - While Life360 is not positioned as a compelling earnings-beat candidate, investors are advised to consider other factors influencing stock performance ahead of the earnings release [17].

Core Viewpoint - Sarepta Therapeutics (SRPT) is anticipated to report a year-over-year decline in earnings due to lower revenues, with a consensus outlook indicating a quarterly loss of $0.71 per share, reflecting a -147.3% change from the previous year, and revenues expected to be $408.53 million, down 38% from the year-ago quarter [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 25, and the stock may rise if the reported numbers exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised down by 45.87% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model suggests that the Most Accurate Estimate for Sarepta is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +2.11% [12]. - The stock currently holds a Zacks Rank of 3, indicating a hold position, which suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Sarepta was expected to post earnings of $0.01 per share but instead reported a loss of -$0.13, resulting in a surprise of -1,400.00% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Context - In the broader context of the Zacks Medical - Biomedical and Genetics industry, Cytokinetics (CYTK) is also expected to report a loss of $1.48 per share, reflecting a year-over-year change of -17.5%, with revenues expected to be $3.89 million, down 77% from the previous year [18][19].

Core Viewpoint - Wall Street anticipates a significant year-over-year increase in earnings for BKV, driven by higher revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - BKV is expected to report quarterly earnings of $0.37 per share, reflecting a year-over-year increase of +3600% [3]. - Revenues are projected to reach $258.05 million, which is an increase of 115.4% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 3.19% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for BKV is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.11% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [10]. - BKV currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat despite the positive Earnings ESP [12]. Historical Performance - In the last reported quarter, BKV exceeded the expected earnings of $0.13 per share by delivering $0.50, resulting in a surprise of +284.62% [13]. - Over the past four quarters, BKV has consistently beaten consensus EPS estimates [14]. Conclusion - While BKV shows potential for an earnings beat based on estimates, the current Zacks Rank and other factors may influence stock performance post-earnings release [15][17].

Core Viewpoint - EuroDry (EDRY) is anticipated to report a year-over-year increase in earnings due to higher revenues for the quarter ending December 2025, with the consensus outlook indicating a significant potential impact on the stock price based on actual results compared to estimates [1][2]. Earnings Expectations - The Zacks Consensus Estimate predicts quarterly earnings of $0.78 per share, reflecting a year-over-year increase of +412% [3]. - Expected revenues are projected to be $16.51 million, which is a 13.8% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2100% higher in the last 30 days, indicating a significant reassessment by analysts [4]. - The Most Accurate Estimate for EuroDry aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [9][10]. - EuroDry currently holds a Zacks Rank of 1, but the combination with an Earnings ESP of 0% complicates predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, EuroDry was expected to post a loss of $0.15 per share but instead reported a loss of -$0.23, resulting in a surprise of -53.33% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Conclusion - While EuroDry is not positioned as a compelling earnings-beat candidate, investors are advised to consider other factors when making decisions regarding the stock ahead of its earnings release [17].

Core Viewpoint - The market anticipates Domino's Pizza (DPZ) will report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Domino's Pizza is expected to post quarterly earnings of $5.36 per share, reflecting a year-over-year increase of +9.6% [3]. - Revenues are projected to reach $1.52 billion, which is a 4.9% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.11% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Domino's Pizza is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.88% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a higher likelihood of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Domino's Pizza currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Domino's Pizza exceeded the expected earnings of $3.96 per share by delivering $4.08, resulting in a surprise of +3.03% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Context - Jack In The Box (JACK), a competitor in the Zacks Retail - Restaurants industry, is expected to report a significant decline in earnings per share of $1.1, down -42.7% year-over-year, with revenues expected to drop by 26.8% [18][19].

Core Viewpoint - Travere Therapeutics (TVTX) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ending December 2025, which could significantly influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.03 per share, reflecting a year-over-year increase of +104.1% [3]. - Expected revenues are projected to be $142.46 million, representing a 90.5% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 17.07% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Travere is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +775.01%, suggesting a bullish outlook on the company's earnings [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of a potential earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Stocks with a positive Earnings ESP and a solid Zacks Rank have historically produced a positive surprise nearly 70% of the time [10]. Historical Performance - In the last reported quarter, Travere was expected to post a loss of $0.31 per share but instead reported earnings of $0.28, resulting in a surprise of +190.32% [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14]. Conclusion - Travere is positioned as a compelling candidate for an earnings beat, but investors should consider other factors that may influence stock performance beyond earnings results [17].

Core Viewpoint - Ardelyx (ARDX) is anticipated to report flat earnings of $0.02 per share for the quarter ended December 2025, with revenues expected to reach $117.57 million, reflecting a 1.2% increase from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 19, and the stock may experience upward movement if earnings exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised down by 50% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +80.00% for Ardelyx, suggesting analysts have become more optimistic about the company's earnings prospects [12]. - The stock currently holds a Zacks Rank of 3, indicating a neutral outlook [12]. Historical Performance - In the last reported quarter, Ardelyx was expected to post a loss of $0.06 per share but instead delivered break-even earnings, resulting in a surprise of +100.00% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Conclusion - Ardelyx is viewed as a strong candidate for an earnings beat, but investors are advised to consider additional factors beyond earnings results when making investment decisions [17].